In all five countries the success rate for the two treatments was assumed to be the same: triple therapy achieved 35% success compared with single therapy which achieved 5%.
In the US, the cost per treatment for triple therapy was $58 compared with single therapy costs of $114; triple therapy dominated single therapy, it was less expensive and more effective.
In Brazil, the cost per treatment for triple therapy was BRL 149 compared with single therapy costs of BRL 43; the incremental cost per additional primary success was BRL 357.
In Chile, the cost per treatment for triple therapy was CLP 48,282 compared with single therapy costs of CLP 20,212; the incremental cost per additional primary success was CLP 95,529.
In Argentina, the cost per treatment for triple therapy was ARS 215 compared with single therapy costs of ARS 64; the incremental cost per additional primary success was ARS 509.
In Columbia, the cost per treatment for triple therapy was COP 143,200 compared with single therapy costs of COP 33,118; the incremental cost per additional primary success was COP 370,870.
Sensitivity analysis related to effectiveness and resource use produced ICER results ranging from: for the US triple remained dominant, for Brazil from BRL 254 to 600; Chile CLP 68,008 to 197,358; Argentina ARS 362 to 855; and Columbia COP 264,024 to 682,609.